Literature DB >> 6451286

Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2'-deoxyuridine.

P W Woodman, A M Sarrif, C Heidelberger.   

Abstract

Isoelectric focusing and studies with 1-(2'-deoxy-beta-D-glucopyranosyl)thymine (GPT), a specific inhibitor of uridine phosphorylase activity, were used to determine the substrate specificities of mammalian pyrimidine nucleoside phosphorylases and their cleavage of 5-fluoro-2'-deoxyuridine (FdUrd). Isoelectric focusing profiles for the cytosol fractions from Ehrlich ascites cells and from Novikoff hepatoma cells each consisted essentially of one peak of nucleoside phosphorylase activity [isoelectric points (pl) 5.4 and 5.8, respectively] that cleaved both uridine and thymidine (dThd), as well as FdUrd. By contrast, cytosol fractions from HeLa (S3) cells, mouse liver, and normal human leukocytes each exhibited a major peak of activity (pl 4.6, 6.5, and 4.9, respectively) that cleaved only dThd and FdUrd, while mouse liver exhibited a second peak (pl 5.2) that cleaved primarily uridine. To distinguish clearly between (a) uridine phosphorylases that cleave primarily uridine and that are inhibited by GPT and (b)dThd phosphorylases that cleave only deoxynucleosides and that are not inhibited by GPT, we propose the term "uridine-deoxyuridine phosphorylases" to define those pyrimidine nucleoside phosphorylases that cleave both uridine and dThd and that are inhibited by GPT. On the basis of this definition and studies with GPT in nonfocused cytosol preparations, we conclude that FdUrd is cleaved to 5-fluorouracil by uridine-deoxyuridine phosphorylase activity in Ehrlich ascites cells and in Novikoff hepatoma cells, and by dThd phosphorylases in mouse liver, in normal human leukocytes, and in HeLa (S3) cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6451286

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Antiviral activity of 5-ethyl-2'-deoxyuridine against herpes simplex viruses in cell culture, mice, and guinea pigs.

Authors:  R F Schinazi; R T Scott; J Peters; V Rice; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Crystallization and preliminary X-ray study of Vibrio cholerae uridine phosphorylase in complex with 6-methyluracil.

Authors:  Igor I Prokofev; Alexander A Lashkov; Azat G Gabdulkhakov; Mariya V Dontsova; Tatyana A Seregina; Alexander S Mironov; Christian Betzel; Al'bert M Mikhailov
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2013-12-24       Impact factor: 1.056

3.  Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism.

Authors:  Christopher P Landowski; Xueqin Song; Philip L Lorenzi; John M Hilfinger; Gordon L Amidon
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

Review 4.  Structural analyses reveal two distinct families of nucleoside phosphorylases.

Authors:  Matthew J Pugmire; Steven E Ealick
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

5.  The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.

Authors:  Yasuhiro Tsume; Tuba Incecayir; Xueqin Song; John M Hilfinger; Gordon L Amidon
Journal:  Eur J Pharm Biopharm       Date:  2013-12-19       Impact factor: 5.571

6.  Metabolic breakdown of [3H]thymidine and the inability to measure human lymphocyte proliferation by incorporation of radioactivity.

Authors:  J Bodycote; S Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

7.  The role of fluorinated pyrimidine analogues in the induction of the in vitro expression of the fragile X chromosome.

Authors:  B Vandamme; I Liebaers; L Hens; J L Bernheim; C Roobol
Journal:  Hum Genet       Date:  1988-08       Impact factor: 4.132

8.  Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.

Authors:  Yasuhiro Tsume; John M Hilfinger; Gordon L Amidon
Journal:  Mol Pharm       Date:  2008-07-25       Impact factor: 4.939

9.  Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.

Authors:  G J Peters; B J Braakhuis; E A de Bruijn; E J Laurensse; M van Walsum; H M Pinedo
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

10.  5-fluorouracil and 5-fluoro-2'-deoxyuridine follow different metabolic pathways in the induction of cell lethality in L1210 leukaemia.

Authors:  C Roobol; G B De Dobbeleer; J L Bernheim
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.